Exjade 125mg. 250mg. 500mg dispersible tablets
PDF Leaflet Revision Date: 15 April 2020
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of chronic iron overload due to blood transfusions and non-transfusion-dependent thalassemia.
Dosage (summary)
Starting dose: 20 mg/kg for transfusion overload; 10 mg/kg for non-transfusion-dependent thalassemia.
Special Populations
- Elderly patients
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; safety in breastfeeding not established.
Key Drug Interactions
- NSAIDs
- Corticosteroids
- Oral bisphosphonates
- Anticoagulants
- Repaglinide
- CYP3A4 substrates
Contraindications
- Hypersensitivity
- Creatinine clearance < 60 mL/min
- Severe hepatic impairment
- Pregnancy and lactation
Common side effects
- Gastrointestinal disturbances
- Skin rash
- Increased serum creatinine
- Elevated liver transaminases
Counselling Points
- Take on an empty stomach
- Monitor renal and hepatic function regularly
- Report any signs of severe skin reactions
Serious warnings
- Risk of gastrointestinal ulceration and hemorrhage
- Hepatic failure reports
- Serious skin reactions
Important Disclaimer
The Exjade 125mg. 250mg. 500mg dispersible tablets professional information leaflet below is the property of Novartis and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
